Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice
- 253 Downloads
To elucidate the neuroprotective effects of the iron chelator desferrioxamine (DFO) and the antioxidant vitamin E on excessive iron-induced free radical damage, a chronic iron-loaded mice model was established. The relationship between striatal iron content, oxidized to reduced glutathione ratio, hydroxyl radical (.OH) levels and dopamine concentrations were observed in DFO or vitamin E pretreated iron-loaded/1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57BL/6 mice. The results demonstrated that both DFO and vitamin E inhibit the iron accumulation and thus reverses the increase in oxidized glutathione (GSSG), oxidized to reduced glutathione ratios, .OH and lipid peroxidation levels. The striatal dopamine concentration was elevated to normal value. Our data suggested that: (1) iron may induce neuronal damage and thus excessive iron in the brain may contribute to the neuronal loss in PD; (2) iron chelators and antioxidants may serve as potential therapeutic agents in retarding the progression of neurodegeneration.
KeywordsIron MPTP DFO vitamin E neurodegeneration
Unable to display preview. Download preview PDF.
- Althaus JS, Andrus PK, Williams CM, Von Voigtlander PF, Cazers AR, Hall ED (1993) The use of salicylate hydroxylation to detect hydroxyl radical generation in ischemic and traumatic brain injury: reversal by tirilazad mesylate (U-74006F). Mol Chem Neuropath 20: 147–162Google Scholar
- Arendash GW, Sengstock GJ, Olanow CW, Barone S Jr, Dunn AJ (1994) Intranigral iron infusion as a model for Parkinson's disease. In: Woodruff ML, Nonneman AJ (eds) Toxin-induced models of neurological disorders. Plenum Press, New York, pp 175–212Google Scholar
- Ceccarelli D, Gallesi D, Giovannini F, Ferrali M, Masini A (1995) Relationship between free iron level and rat liver mitochondrial dysfunction in experimental dietary iron overload. Biochem Biophy Res Commun 209: 53–59Google Scholar
- Fahn S (1992) A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease. Ann Neurol 32 [Suppl]: 128–132Google Scholar
- Jenner P (1993) Altered mitochondria function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand 87 [Suppl 46]: 6–13Google Scholar
- Parkinson Study Group (1989a) Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 321: 1364–1371Google Scholar
- Parkinson Study Group (1989b) DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 46: 1052–1060Google Scholar
- Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328: 176–183Google Scholar
- Taylor E, Morgan E(1990) Developmental changes in transferrin and iron uptake by the brain in the rat. Dev Brain Res 55: 35–42Google Scholar
- Youdim MBH, Ben-Shachar D, Eshel G, Finberg JPM, Riederer P (1993) The neurotoxicity of iron and nitric oxide: relevance to the etiology of Parkinson's disease. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y (eds) Advances in neurology. Raven Press, New York, pp 259–266Google Scholar